Received Sep 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y010802 | — |
Pharmacist reports patient that is pregnant received her first dose of GARDASIL 9 yesterday. Pharmacist consents to follow-up via email but does not wish to provide patient information at time of call due to not having consent from patient. No additi; No additional adverse event reported; Information has been received from Business Partner/CRO on 12-Aug-2025. This spontaneous Prospective pregnancy report was received from a Pharmacist and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 11-Aug-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #Y010802, expiration date: 01-Jan-2027), dose number 1, for an unknown indication. On an unknown date, the patient reported that the patient was pregnant received her first dose of GARDASIL 9 yesterday (Vaccine exposure during pregnancy). No additional adverse event was reported. This pregnancy involved 1 fetus. The patient's gravidity was reported as 0. The patient's parity was reported as 1.